A61K 38/2046
Il-7
Official title: {il-7}
A61K38/2046 (Il-7) appears on 119 US grants and 251 published applications in this corpus.
Search patents in A61K- Granted patents
- 119
- Published applications
- 251
- Assignees
- 144
- Inventors
- 443
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 9 |
| 2003 | 3 | 0 |
| 2004 | 1 | 6 |
| 2005 | 1 | 6 |
| 2006 | 1 | 4 |
| 2007 | 0 | 3 |
| 2008 | 1 | 1 |
| 2009 | 0 | 3 |
| 2010 | 2 | 6 |
| 2011 | 2 | 7 |
| 2012 | 5 | 5 |
| 2013 | 3 | 5 |
| 2014 | 5 | 11 |
| 2015 | 3 | 9 |
| 2016 | 8 | 9 |
| 2017 | 6 | 13 |
| 2018 | 7 | 13 |
| 2019 | 7 | 16 |
| 2020 | 5 | 8 |
| 2021 | 4 | 16 |
| 2022 | 11 | 29 |
| 2023 | 12 | 28 |
| 2024 | 9 | 18 |
| 2025 | 9 | 16 |
| 2026 | 7 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Nant cancer vaccine16 Jun 2026US 12,653,874 B2ImmunityBio, Inc.
- Conjugates of an il-7 moiety and a polymer19 May 2026US 12,629,407 B2Nektar Therapeutics
- Glypican-2-binding moieties, chimeric antigen receptors and uses thereof21 Apr 2026US 12,606,635 B2Nanjing Legend Biotech Co., Ltd.
- CBL inhibitors and compositions for expansion of immune cells7 Apr 2026US 12,594,263 B2Nurix Therapeutics, Inc.
- Fusion cytokine compositions and methods of use thereof13 Aug 2026US 2026/0232779 A1Wisconsin Alumni Research Foundation
- Methods of treating a tumor with an unmethylated mgmt promoter6 Aug 2026US 2026/0224665 A1NeoImmuneTech, Inc.
- Treatment of cancer with immune stimulators6 Aug 2026US 2026/0224667 A1Sciclone Pharmaceuticals International (Sg) Pte. Ltd.
- Modulation of pd-1 signaling for treatment of diseases30 Jul 2026US 2026/0216168 A1Wuhan University
- Embolics with immune-enhancing anti-carcinogenic properties25 Jun 2026US 2026/0174894 A1Bard Peripheral Vascular, Inc.
Most cited
By later US patents
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Adoptive cell therapy with young T cells191US 8,383,099 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013
- Adoptive cell therapy with young T cells137US 9,074,185 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy98US 8,287,857 B2The United States of America as represented by the Secretary of the Deparment of Health and Human Services · 2012
- Adoptive immunotherapy with interleukin-740US 5,229,115 AImmunex Corporation · 1993